Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANI Pharmaceuticals Inc.

www.anipharmaceuticals.com

Latest From ANI Pharmaceuticals Inc.

ANI Strikes Deal With Coeptis For Seven Development-Stage Assets

Continuing its acquisition streak, ANI Pharmaceuticals has bought a pipeline of seven development-stage generics from Coeptis Pharmaceuticals for $2.3m in cash and up to $12m in development and commercial milestone payments.

Deals Strategy

ANI Pledges To Keep Snapping Up Assets And Partnering

US niche generics and brands player ANI Pharmaceuticals intends to keep using its cash flow to fund product acquisitions and partnerships, particularly in the injectables arena.


Business Strategies Deals

Finance Watch: Recent Offerings Show Some Companies Were Ready For The Government Shutdown

Public Company Edition: The usual mid-January surge in public offerings hasn't happened this year, since the SEC can't process new filings, but Alnylam, Acceleron and others apparently were prepared for a lengthy shutdown. Also, ARM reports cell and gene therapy financing data.

Financing Business Strategies

Deal Watch: Pfizer Begins 2018 With Two Deals, Including ALS Tie-Up With Sangamo

In addition to its latest collaboration with Sangamo, Pfizer also teams with Arvinas on protein-degradation therapies. AstraZeneca sells off four mature products to ANI, while Summit enhances its antibiotic capabilities with Discuva buyout and out-licenses Latin American rights to ridinilazole.

Deals Business Strategies
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
    • Generic Drugs
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • ANIP Acquisition Co.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • ANI Pharmaceuticals Inc.
  • Senior Management
  • Arthur S Przybyl, Pres. & CEO
    Stephen P Carey, VP, CFO
    Robert W Schrepfer, SVP, Bus. Dev. & Spec. Sales
  • Contact Info
  • ANI Pharmaceuticals Inc.
    Phone: (218) 634-3500
    210 Main St. W.
    Baudette, MN 56623
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register